{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:45:20Z","timestamp":1788875120593,"version":"build-2803163510"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Antibody-drug conjugates (ADC) are emerging therapies with promising results in the treatment of solid tumors. In this study, we aimed to evaluate biomarker expression of ADCs, including folate receptor alpha (FOLR1), Nectin-4, trophoblast cell surface antigen 2 (Trop-2), and tissue factor (TF) in a diverse cohort of gestational trophoblastic disease. Immunohistochemistry for FOLR1, Nectin-4, Trop-2, and TF was evaluated in tissue microarray of 18 complete hydatidiform moles (CHM) and whole tissue sections of 62 gestational trophoblastic neoplasia (GTN) by 2 gynecologic pathologists. Western blotting for FOLR1, Nectin-4, and Trop-2 was performed in JEG-3 and JAR choriocarcinoma cell lines, 2 CHM and 3 GTN clinical samples. Results: The overall immunohistochemical positive rate in GTN was 11% for FOLR1, 59% for Nectin-4, 38% for Trop-2, and 26% for TF. Choriocarcinomas showed 27% positivity for FOLR1, 75% for Nectin-4, 40% for Trop-2, and 25% for TF. Epithelioid trophoblastic tumors (ETT) were positive for Nectin-4 in 58%, for Trop-2 in 79%, and for TF in 67% of cases\ufeff. Placental site trophoblastic tumors were positive only for Nectin-4 (23% of cases). In CHM, only Nectin-4 revealed a higher degree of expression and limited staining for the other markers. Western blotting showed FOLR1 expression in CHM, JEG-3, and JAR; Nectin-4 in CHM and PSTT; and Trop-2 in CHM, JEG-3, and choriocarcinoma. Conclusion: A subset of GTN shows expression for FOLR1, Nectin-4, Trop-2, and TF, particularly choriocarcinoma \ufeffand ETT. These results suggest that patients with GTN could potentially benefit from ADC treatment.<\/jats:p>","DOI":"10.1097\/pgp.0000000000001119","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:00:33Z","timestamp":1752253233000},"page":"28-38","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Antibody-drug Conjugate Biomarker Expression in Gestational Trophoblastic Disease: Folate Receptor Alpha, Nectin-4, Trop-2, and Tissue Factor"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9603-9783","authenticated-orcid":false,"given":"Lawrence Hsu","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School"},{"name":"Department of Pathology, Massachusetts General Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen T.","family":"Hasselblatt","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, New England Trophoblastic Disease Center, Department of Obstetrics and Gynecology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Parra-Herran","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, New England Trophoblastic Disease Center, Department of Obstetrics and Gynecology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross S.","family":"Berkowitz","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, New England Trophoblastic Disease Center, Department of Obstetrics and Gynecology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Quade","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Elias","sequence":"additional","affiliation":[{"name":"Section of Gynecologic Oncology, Obstetrics and Gynecology Institute, Taussig Cancer Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(10)60280-2","article-title":"Gestational trophoblastic disease","volume":"376","author":"Seckl","year":"2010","journal-title":"Lancet"},{"issue":"suppl 1","key":"R2-20251215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ijgo.13877","article-title":"Diagnosis and management of gestational trophoblastic disease: 2021 update","volume":"155","author":"Ngan","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/PGP.0000000000000305","article-title":"PD-L1 expression in human placentas and gestational trophoblastic diseases","volume":"36","author":"Veras","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000533972","article-title":"Immunotherapy for gestational trophoblastic neoplasia: a new paradigm","volume":"89","author":"Baas","year":"2024","journal-title":"Gynecol Obstet Invest"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"100260","DOI":"10.1016\/j.clinsp.2023.100260","article-title":"Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia\u2014systematic review with a presentation of the first 4 Brazilian cases","volume":"78","author":"Braga","year":"2023","journal-title":"Clinics (Sao Paulo)"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.21873\/anticanres.13355","article-title":"Lapatinib inhibits amphiregulin-induced BeWo choriocarcinoma cell proliferation by reducing ERK1\/2 and AKT signaling pathways","volume":"39","author":"Pires","year":"2019","journal-title":"Anticancer Res"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/S0002-9378(12)91825-6","article-title":"Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease","volume":"170","author":"Cameron","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"R9-20251215","first-page":"101","article-title":"c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma","volume":"43","author":"Fulop","year":"1998","journal-title":"J Reprod Med"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/14737140.2023.2236793","article-title":"Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer","volume":"23","author":"Porter","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"R17-20251215","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with her2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"R21-20251215","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1007\/s43032-021-00634-y","article-title":"Loss of selenoprotein iodothyronine deiodinase 3 expression correlates with progression of complete hydatidiform mole to gestational trophoblastic neoplasia","volume":"28","author":"St. Laurent","year":"2021","journal-title":"Reproductive Sciences"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.placenta.2009.11.017","article-title":"Expression of folate transporters in human placenta and implications for homocysteine metabolism","volume":"31","author":"Solanky","year":"2010","journal-title":"Placenta"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.placenta.2015.12.007","article-title":"Relationship between folate transporters expression in human placentas at term and birth weights","volume":"38","author":"Caviedes","year":"2016","journal-title":"Placenta"},{"key":"R26-20251215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/ph10030072","article-title":"Folate receptor-positive gynecological cancer cells: in vitro and in vivo characterization","volume":"10","author":"Siwowska","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"R28-20251215","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF01207263","article-title":"Characterization of the folate receptor in human molar placenta","volume":"16","author":"Holm","year":"1996","journal-title":"Biosci Rep"},{"key":"R30-20251215","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"R31-20251215","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12881-018-0681-y","article-title":"Potential role for nectin-4 in the pathogenesis of pre-eclampsia: a molecular genetic study","volume":"19","author":"Ito","year":"2018","journal-title":"BMC Med Genet"},{"key":"R32-20251215","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.78.8.5147","article-title":"Human trophoblast cell-surface antigens defined by monoclonal antibodies","volume":"78","author":"Lipinski","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R33-20251215","doi-asserted-by":"crossref","first-page":"e1480","DOI":"10.1093\/oncolo\/oyae168","article-title":"Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors","volume":"29","author":"Morgenstern-Kaplan","year":"2024","journal-title":"Oncologist"},{"key":"R34-20251215","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"key":"R37-20251215","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R38-20251215","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/0002-9378(89)90314-1","article-title":"Characterization of pure human first-trimester cytotrophoblast cells in long-term culture: growth pattern, markers, and hormone production","volume":"160","author":"Yagel","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"R39-20251215","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2024.07.055","article-title":"Unveiling the placental secrets: exploring histopathological changes and TROP2 expression in intrahepatic cholestasis of pregnancy","volume":"154","author":"Ozalp","year":"2024","journal-title":"Placenta"},{"key":"R40-20251215","first-page":"4011","article-title":"Limitation of differential expression of HLA-A,B,C antigens on choriocarcinoma cell lines by messenger RNA for HLA heavy chain but not by beta 2-microglobulin","volume":"44","author":"Kawata","year":"1984","journal-title":"Cancer Res"},{"key":"R42-20251215","first-page":"e1699","article-title":"Systematic study of tissue factor expression in solid tumors","volume":"6","author":"de Bono","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"R43-20251215","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2407-11-263","article-title":"Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor","volume":"11","author":"Cocco","year":"2011","journal-title":"BMC Cancer"},{"key":"R44-20251215","first-page":"271","article-title":"Single-center experience in managing epithelioid trophoblastic tumors","volume":"63","author":"Lin","year":"2018","journal-title":"J Reprod Med"},{"key":"R45-20251215","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ygyno.2015.03.006","article-title":"Epithelioid trophoblastic tumor: a single institution case series at the New England Trophoblastic Disease Center","volume":"137","author":"Davis","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R46-20251215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0038-1653724","article-title":"Tissue factor activity of syncytiotrophoblast plasma membranes and tumoral trophoblast cells in culture","volume":"73","author":"Reverdiau","year":"1995","journal-title":"Thromb Haemost"},{"key":"R47-20251215","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1160\/TH04-01-0033","article-title":"Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis","volume":"92","author":"Aharon","year":"2004","journal-title":"Thromb Haemost"},{"key":"R48-20251215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood.V76.1.86.86","article-title":"Tissue factor: identification and characterization of cell types in human placentae","volume":"76","author":"Faulk","year":"1990","journal-title":"Blood"},{"key":"R49-20251215","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0002-9378(99)70457-6","article-title":"Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome","volume":"181","author":"Lakasing","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"R50-20251215","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0049-3848(90)90148-6","article-title":"Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody","volume":"59","author":"Fleck","year":"1990","journal-title":"Thromb Res"},{"key":"R51-20251215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2017.11.029","article-title":"Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: a case from the New England Trophoblastic Disease Center, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute","volume":"148","author":"Worley","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R52-20251215","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S1470-2045(21)00460-5","article-title":"Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial","volume":"22","author":"Cheng","year":"2021","journal-title":"Lancet Oncol"},{"key":"R53-20251215","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11626-017-0145-2","article-title":"In vitro evaluation of combination of EGCG and erlotinib with classical chemotherapeutics on JAR cells","volume":"53","author":"Telli","year":"2017","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"R54-20251215","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41388-022-02251-8","article-title":"ATR and CDK4\/6 inhibition target the growth of methotrexate-resistant choriocarcinoma","volume":"41","author":"Georgiou","year":"2022","journal-title":"Oncogene"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:05:55Z","timestamp":1765814755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000001119","relation":{},"ISSN":["0277-1691","1538-7151"],"issn-type":[{"value":"0277-1691","type":"print"},{"value":"1538-7151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}